Beckett M L, Wright G L
Department of Microbiology and Immunology, Eastern Virginia Medical School, Norfolk 23501, USA.
Int J Cancer. 1995 Sep 15;62(6):703-10. doi: 10.1002/ijc.2910620610.
A recently identified, high m.w. human tumor antigen, reactive with monoclonal antibody (MAb) PD41 and designated prostate mucin antigen (PMA), was found to have expression highly restricted to prostate carcinomas. Both biochemical and immunological characteristics of this antigen and its relationship to other tumor-associated mucins and various species of submaxillary mucins were evaluated. Immunohistochemical examination of submaxillary tissues revealed differential expression of this antigen and other human tumor-associated mucins, with MAb PD41 expression found only in bovine submaxillary gland serous cells. Neuraminidase treatment enhanced antibody binding by 50%, suggesting partial masking of the PD41 epitope by sialic acid. Antigenicity was reduced by treatment with alkaline-borohydride, sodium metaperiodate, beta-galactosidase, O-glycanase, and various proteolytic enzymes. MAb PD41 antibody binding also could be significantly reduced by selected lectins and sugars suggesting that the immunodominant carbohydrate involved in the epitope was an O-linked oligosaccharide containing N-acetyl galactosamine as a major component. This antigen was further distinguished from T, Tn, or Sialyl-Tn antigens and blood group carbohydrate antigens by radioimmunometric analyses. Cross-blocking and double determinant RIA experiments also showed a distinction between the PD41 epitope and several well-characterized tumor-associated mucin antigens such as MUCI, CEA, M344, OCI25, and AR3 as well as bovine submaxillary core protein. Our results indicate that the PD41-reactive epitope is a non-acidic O-linked carbohydrate or glycopeptide epitope with restricted expression in prostate carcinomas and bovine submaxillary glands. This expression is distinct from other mucin-like tumor-associated antigens identified in human prostate carcinomas.
一种最近鉴定出的高分子量人类肿瘤抗原,可与单克隆抗体(MAb)PD41发生反应,被命名为前列腺粘蛋白抗原(PMA),发现其表达高度局限于前列腺癌。对该抗原的生化和免疫特性及其与其他肿瘤相关粘蛋白和各种颌下粘蛋白种类的关系进行了评估。对颌下组织的免疫组织化学检查显示了该抗原和其他人类肿瘤相关粘蛋白的差异表达,仅在牛颌下腺浆液细胞中发现了MAb PD41的表达。神经氨酸酶处理使抗体结合增加了50%,表明唾液酸对PD41表位有部分掩盖作用。用碱性硼氢化物、偏高碘酸钠、β-半乳糖苷酶、O-聚糖酶和各种蛋白水解酶处理后,抗原性降低。选定的凝集素和糖类也可显著降低MAb PD41抗体的结合,这表明表位中涉及的免疫显性碳水化合物是一种以N-乙酰半乳糖胺为主要成分的O-连接寡糖。通过放射免疫分析,该抗原进一步与T、Tn或唾液酸化Tn抗原以及血型碳水化合物抗原区分开来。交叉阻断和双决定簇放射免疫分析实验也表明,PD41表位与几种特征明确的肿瘤相关粘蛋白抗原如MUCI、CEA、M344、OCI25和AR3以及牛颌下核心蛋白之间存在差异。我们的结果表明,PD41反应性表位是一种非酸性的O-连接碳水化合物或糖肽表位,在前列腺癌和牛颌下腺中表达受限。这种表达与在人类前列腺癌中鉴定出的其他粘蛋白样肿瘤相关抗原不同。